Law360, New York (October 12, 2009) -- Onyx Pharmaceuticals Inc., a biopharmaceutical company specializing in cancer treatments, announced Monday that it had agreed to purchase Proteolix Inc. for an initial cash payment of $276 million.
According to a statement from Onyx, the total purchase price for Proteolix, a private biopharmaceutical company that focuses on treatments for blood and other cancers, could range as high as...
